Roche Accutane Generic Forecast Assumes Hesitancy To Switch Risk Plans

Roche is projecting a relatively gentle generic erosion curve for Accutane based on the reluctance of patients and physicians to switch from the branded pregnancy risk management program, U.S. North America CEO George Abercrombie suggested